Using Radiation Therapy to Reduce Recurrence in DCIS

Video
Conference|San Antonio Breast Cancer Symposium (SABCS)

Cancer Network spoke with Dr. Carmen Bergom about advancements in the treatment of DCIS and the importance of using local recurrence patterns to help guide future research.

Cancer Network spoke with Dr. Carmen Bergom about advancements in the treatment of DCIS and the importance of using local recurrence patterns to help guide future research.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content
Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.

DCISionRT Enhances DCIS Risk Stratification Beyond Clincopathology

Roman Fabbricatore
August 8th 2025
Article
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
August 8th 2025
Podcast
Results from the phase 3 VIKTORIA-1 trial showed gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival.

Gedatolisib Combos Improve PFS in Advanced PIK3CA Wild-Type Breast Cancer

Tim Cortese
August 8th 2025
Article
Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
August 8th 2025
Podcast
No Breast Cancer Events Noted When Breastfeeding After ET in HR+ Disease

No Breast Cancer Events Noted When Breastfeeding After ET in HR+ Disease

Ariana Pelosci
August 8th 2025
Article
The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer

Roman Fabbricatore
August 8th 2025
Article